Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Drug therapy: Preclinical oncology

Literature DB >> 26667971

Drug therapy: Preclinical oncology - reporting transparency needed.

Eric E Gardner¹, Charles M Rudin².

Abstract

Mesh：

Substances：

Year: 2015 PMID： 26667971 DOI： 10.1038/nrclinonc.2015.216

Source DB: PubMed Journal: Nat Rev Clin Oncol ISSN： 1759-4774 Impact factor: 66.675

Keyword Cloud
References

× No keyword cloud information.

10 in total

1. Drug development: Raise standards for preclinical cancer research.

Authors: C Glenn Begley; Lee M Ellis
Journal: Nature Date: 2012-03-28 Impact factor: 49.962

Review 2. Preclinical mouse cancer models: a maze of opportunities and challenges.

Authors: Chi-Ping Day; Glenn Merlino; Terry Van Dyke
Journal: Cell Date: 2015-09-24 Impact factor: 41.582

3. Translational value of mouse models in oncology drug development.

Authors: Stephen E Gould; Melissa R Junttila; Frederic J de Sauvage
Journal: Nat Med Date: 2015-05 Impact factor: 53.440

4. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Authors: Sandrine Faivre; Catherine Delbaldo; Karina Vera; Caroline Robert; Stéphanie Lozahic; Nathalie Lassau; Carlo Bello; Samuel Deprimo; Nicoletta Brega; Giorgio Massimini; Jean-Pierre Armand; Paul Scigalla; Eric Raymond
Journal: J Clin Oncol Date: 2005-11-28 Impact factor: 44.544

5. A call for transparent reporting to optimize the predictive value of preclinical research.

Authors: Story C Landis; Susan G Amara; Khusru Asadullah; Chris P Austin; Robi Blumenstein; Eileen W Bradley; Ronald G Crystal; Robert B Darnell; Robert J Ferrante; Howard Fillit; Robert Finkelstein; Marc Fisher; Howard E Gendelman; Robert M Golub; John L Goudreau; Robert A Gross; Amelie K Gubitz; Sharon E Hesterlee; David W Howells; John Huguenard; Katrina Kelner; Walter Koroshetz; Dimitri Krainc; Stanley E Lazic; Michael S Levine; Malcolm R Macleod; John M McCall; Richard T Moxley; Kalyani Narasimhan; Linda J Noble; Steve Perrin; John D Porter; Oswald Steward; Ellis Unger; Ursula Utz; Shai D Silberberg
Journal: Nature Date: 2012-10-11 Impact factor: 49.962

Review 10. Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments.

Authors: Valerie C Henderson; Jonathan Kimmelman; Dean Fergusson; Jeremy M Grimshaw; Dan G Hackam
Journal: PLoS Med Date: 2013-07-23 Impact factor: 11.069

10 in total

Drug therapy: Preclinical oncology - reporting transparency needed.

1. Drug development: Raise standards for preclinical cancer research.

Review 2. Preclinical mouse cancer models: a maze of opportunities and challenges.

3. Translational value of mouse models in oncology drug development.

4. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

5. A call for transparent reporting to optimize the predictive value of preclinical research.

Review 6. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research.

Review 7. Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.

8. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer.

9. A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib.

Review 10. Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments.